Biovail Receives Canadian Approval for Ralivia(TM) (FinanzNachrichten)
Biovail Corporation ( Nachrichten ) (NYSE:BVF)(TSX:BVF) today announced that the Therapeutic Products Directorate (TPD) Canada has issued a Notice of Compliance (NOC) for 100mg, 200mg and 300mg tablet strengths of Ralivia , the Company ' s once-daily, extended-release formulation of tramadol hydrochloride indicated for the management of pain of moderate severity in patients who require ...

Biovail Receives Canadian Approval for Ralivia(TM) (Business Wire via Yahoo! Finance)
TORONTO----Biovail Corporation today announced that the Therapeutic Products Directorate Canada has issued a Notice of Compliance for 100mg, 200mg and 300mg tablet strengths of Ralivia, the Company's once-daily, extended-release formulation of tramadol hydrochloride indicated for the management of pain of moderate severity in patients who require continuous treatment for several days or more.

Trends in spending (eyeforpharma.com)
, in 1996, total spending on pharma promotion was $11.4 billion. By 2005, that amount had grown to $29.9 billion. Total real spending on promotion, from 1996 to 2005, increased at an average rate of 10.6%. The percentage of sales spent on promotion grew from 14.2% in 1996 to 18.2% in 2005.